Drug Profile
Research programme: phosphodiesterase-4 inhibitors - Curacyte
Alternative Names: CD160130Latest Information Update: 16 Oct 2012
Price :
$50
*
At a glance
- Originator Curacyte AG
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia
Most Recent Events
- 26 Aug 2011 Discontinued - Preclinical for Chronic lymphocytic leukaemia in Germany (unspecified route)
- 25 Sep 2007 Preclinical trials in Chronic lymphocytic leukaemia in Germany (unspecified route)
- 24 Sep 2007 Research programme: phosphodiesetare-4 inhibitors - Curacyte received Orphan Drug status for Chronic lymphocytic leukaemia in European Union